INBRAIN Neuroelectronics completes patient recruitment for first-in-human study evaluating its graphene cortical interface

The study (NCT06368310), sponsored by the University of Manchester and conducted with Northern Care Alliance NHS Foundation Trust, evaluated INBRAIN’s graphene-based cortical interface during neurosurgical procedures for brain tumor resection. The primary objective was to assess safety, with secondary objectives focused on signal quality, stability, stimulation capability, and suitability for intraoperative use with standard surgical tooling and recording equipment.

INBRAIN Neuroelectronics has announced that it has completed patient recruitment in its first-in-human study evaluating its graphene cortical interface. A total of ten patients were recruited into its first-in-human study, and eight patients were treated surgically, with no perioperative device failure observed during use. Complete datasets were obtained from eight patients.The study (NCT06368310), sponsored by the University of Manchester and conducted with Northern Care Alliance NHS Foundation Trust, evaluated INBRAIN’s graphene-based cortical interface during neurosurgical procedures for brain tumor resection. The primary objective was to assess safety, with secondary objectives focused on signal quality, stability, stimulation capability, and suitability for intraoperative use with standard surgical tooling and recording equipment.

Read More Graphene-Info – Graphene industry portal